|  |  |  |
| --- | --- | --- |
| A close-up of a logo  Description automatically generated | | A logo with a spiral in the center  Description automatically generated |
| Treatments for renal cell carcinoma [ID6186]: A Pathways Pilot Appraisal  Appendix Q:  Economic results | | |
| **Produced by** | **Peninsula Technology Assessment Group (PenTAG)**  **University of Exeter Medical School**  **South Cloisters**  **St Luke’s Campus**  **Heavitree Road**  **Exeter**  **EX1 2LU** | |
| **Correspondence to** | Professor Dawn Lee  3.09 South Cloisters, St Luke’s Campus, Heavitree Road, Exeter, EX1 2LU; [D.Lee7@exeter.ac.uk](mailto:D.Lee7@exeter.ac.uk) | |
| **Source of funding** | This report was commissioned by the NIHR Evidence Synthesis Programme as project number NIHR136008. | |
| **This appendix is linked to report** | **Lee et al. Treatments for renal cell carcinoma [ID6186]: A Single Technology Appraisal. Peninsula Technology Assessment Group (PenTAG), 2023.** | |
| **Copyright** | © 2023, PenTAG, University of Exeter. Copyright is retained by Ipsen for tables and figures copied and/or adapted from the company submissions and other submitted company documents. | |
|  | |  |

Table of contents

[Appendix Q. Economic evidence 5](#_Toc143182831)

List of abbreviations

|  |  |
| --- | --- |
| Abs | absolute |
| AE | Adverse Event |
| ASCO | American Society Of Clinical Oncology |
| AUC | Area Under The Curve |
| BSC | Best Supportive Care |
| cabo | cabozantinib |
| CDF | Cancer Drugs Fund |
| CE | Cost Effectiveness |
| DSU | Decision Support Unit |
| EAG | External Assessment Group |
| EOL | End Of Life |
| evero | everolimus |
| fav | favourable |
| FP | Fractional Polynomial |
| Gen | general |
| HFS | Hand Foot Syndrome |
| HR | Hazard Ratio |
| HRQL | Health-Related Quality of Life |
| ICER | Incremental Cost-Effectiveness Ratio |
| int | intermediate |
| IO | Immune-Oncology |
| IPD | Individual Patient Data |
| ipi | ipilimumab |
| IV | Intravenous |
| KM | Kaplan-Meier |
| lenv | lenvatinib |
| LY | Life Year(s) |
| LYG | Life Year(s) Gained |
| MRU | Medical Resource Use |
| NICE | National Institute For Health And Care Excellence |
| nivo | nivolumab |
| NMA | Network Meta-Analysis |
| OS | Overall Survival |
| PAS | Patient Access Scheme |
| pazo | pazopanib |
| PD | Progressed Disease |
| pem | pembrolizumab |
| PFS | Progression Free Survival |
| PH | Proportional Hazards |
| Pop | population |
| PPS | Post Progression Survival |
| Prop | proportional |
| QALY | Qualiy Adjusted Life Year(s) |
| QC | Quality check |
| RCC | Renal cell carcinoma |
| RDI | Relative Dosing Intensity |
| RWE | Real World Evidence |
| SF | shortfall |
| SOC | Standard of care |
| suni | sunitinib |
| TA | Technology appraisal |
| tivo | tivozanib |
| TKI | Tyrosine Kinase Inhibitor |
| TTD | Time To Discontinuation |
| TTP | Time To Progression |
| UK | United Kingdom |
| vs | versus |

# Economic evidence

This document contains automated reporting from R. Confidentiality marking needs to be applied separately.